David W. Moskowitz MD
WGNU 920 AM
St. Louis Urban Forum
Tel. 314-454-0400 / 877-537-1329
ST. LOUIS—January 11, 2010—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced that tomorrow will be its first radio show on WGNU 920 AM. The show, called “To Your Health,” will be emceed by GenoMed’s CEO and Chief Medical Officer, David Moskowitz MD every second Tuesday from 8 to 9 am, central time. Patients are encouraged to call in for free medical advice.
Dr. Moskowitz said, “It’s not enough to discover how to prevent 90% of dialysis, as I did 15 years ago, if people don’t hear about it. So far, I’ve been amazed at how little help I’ve gotten. To actually do public health, GenoMed must get the word out, even if it means starting our own radio show. How many companies are willing to go that far?”
Dr. Moskowitz continued, “My paper showing how to prevent at least 90% of kidney failure was published in September, 2002. Although kidney failure claims the lives of 300 Americans every day, it affects African-Americans 5 times more, and Hispanics 3 times more, than whites. Medicare currently spends $40 billion a year on this disease, but so far has shown absolutely no interest in eliminating it.”
Dr. Moskowitz ended by saying, “Public health starts at home. But the beauty of the Internet is that anybody in the world can listen to our show, and email or call in questions.”
About GenoMed (www.genomed.com)
GenoMed was founded in 2001 by Dr. David Moskowitz, a kidney specialist. The company recently began a “Dialysis-Free in 5” campaign: it will gladly work with any community in the world that wants to eliminate 90% of dialysis within 5 years. GenoMed hopes to make St. Louis dialysis-free by 2015.
Safe Harbor Statement
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.’s (the Company’s) finances and treatments. The words or phrases “ought to,” “should,” “could,” “may,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.